Metastatic Gastric Cancer Clinical Trials in Beijing, Beijing Municipality
3 recruitingBeijing, Beijing Municipality, China
Showing 1–3 of 3 trials
Recruiting
Phase 1
BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
Gastroesophageal Junction AdenocarcinomaAdvanced or Metastatic Gastric Cancer
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.80 enrolled1 locationNCT06773312
Recruiting
Phase 3
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd486 enrolled1 locationNCT06177041
Recruiting
Phase 1Phase 2
Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
Metastatic Gastric Cancer
CNBG-Virogin Biotech (Shanghai) Ltd.43 enrolled1 locationNCT06008925